Erica N Evans

2.9k total citations
44 papers, 1.2k citations indexed

About

Erica N Evans is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Erica N Evans has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 13 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Erica N Evans's work include Mast cells and histamine (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Erica N Evans is often cited by papers focused on Mast cells and histamine (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Erica N Evans collaborates with scholars based in United States, United Kingdom and Germany. Erica N Evans's co-authors include Daniel G. Tenen, Hanna S. Radomska, Juswinder Singh, William Westlin, Christoph Lengauer, Mariana Nacht, Michael P. Sheets, Heather Lounsbury, Alexandra K. Gardino and Russell C. Petter and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Erica N Evans

43 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Erica N Evans 487 379 288 232 191 44 1.2k
Sebastian Herzog 713 1.5× 485 1.3× 214 0.7× 296 1.3× 122 0.6× 43 1.4k
Albert G. Tsai 632 1.3× 365 1.0× 153 0.5× 108 0.5× 114 0.6× 26 1.2k
Susan O’Brien 489 1.0× 205 0.5× 533 1.9× 587 2.5× 231 1.2× 56 1.3k
Pia Ragno 761 1.6× 312 0.8× 164 0.6× 476 2.1× 82 0.4× 53 1.8k
Giorgia Simonetti 1.0k 2.1× 778 2.1× 382 1.3× 377 1.6× 224 1.2× 91 2.2k
Donatella Venturelli 1.1k 2.2× 283 0.7× 418 1.5× 638 2.8× 211 1.1× 58 1.8k
Zongdong Li 1.2k 2.4× 473 1.2× 144 0.5× 324 1.4× 199 1.0× 26 1.9k
Lorraine Tracey 580 1.2× 216 0.6× 154 0.5× 97 0.4× 181 0.9× 20 1.1k
Sonia Minuzzo 824 1.7× 315 0.8× 155 0.5× 210 0.9× 159 0.8× 49 1.5k
Samuli Eldfors 403 0.8× 255 0.7× 252 0.9× 286 1.2× 273 1.4× 41 1.0k

Countries citing papers authored by Erica N Evans

Since Specialization
Citations

This map shows the geographic impact of Erica N Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica N Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica N Evans more than expected).

Fields of papers citing papers by Erica N Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica N Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica N Evans. The network helps show where Erica N Evans may publish in the future.

Co-authorship network of co-authors of Erica N Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Erica N Evans. A scholar is included among the top collaborators of Erica N Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica N Evans. Erica N Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wade, Jon, Erica N Evans, Michael A. Suster, et al.. (2025). Use of the microfluidic impedance red cell assay in sickle cell disease. Blood Advances. 9(15). 4004–4015.
2.
Bartholdy, Boris, Yukiya Yamamoto, Erica N Evans, et al.. (2022). PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development. Communications Biology. 5(1). 961–961. 21 indexed citations
3.
DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. 27(12). 2183–2191. 88 indexed citations
4.
Evans, Erica N, et al.. (2019). P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models. Journal of Thoracic Oncology. 14(10). S701–S701. 14 indexed citations
5.
Lübke, Johannes, Nicole Naumann, Juliana Schwaab, et al.. (2019). Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia. 33(5). 1195–1205. 33 indexed citations
6.
Erickson, Britt, et al.. (2019). An innovative medical student curriculum to address Human Papillomavirus vaccine hesitancy. PEDIATRICS. 144(2_MeetingAbstract). 237–237. 1 indexed citations
7.
Gebreyohannes, Yemarshet K., Agnieszka Woźniak, Jasmien Wellens, et al.. (2018). Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. Clinical Cancer Research. 25(2). 609–618. 57 indexed citations
8.
Piotrowska, Zofia, Hideko Isozaki, Jochen K. Lennerz, et al.. (2018). MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement. Journal of Thoracic Oncology. 13(10). S451–S451. 1 indexed citations
9.
Subbiah, Vivek, Matthew H. Taylor, Mimi I. Hu, et al.. (2018). Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors. Cancer Research. 78(13_Supplement). CT043–CT043. 22 indexed citations
10.
Evans, Erica N, Fiona Taylor, H.‐P. Horny, et al.. (2016). Development and Content Validity of the Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF). Value in Health. 19(7). A386–A386. 2 indexed citations
11.
12.
Evans, Erica N, Richland Tester, Russell Karp, et al.. (2013). Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans. Journal of Pharmacology and Experimental Therapeutics. 346(2). 219–228. 171 indexed citations
13.
Lester, Gillian M. Schiralli, Hisashi Akiyama, Erica N Evans, et al.. (2012). Interleukin 2-inducible T cell kinase (ITK) facilitates efficient egress of HIV-1 by coordinating Gag distribution and actin organization. Virology. 436(1). 235–243. 11 indexed citations
14.
Evans, Erica N, Zafer Koçak, S. Zhou, et al.. (2006). Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer?. Cytokine. 35(3-4). 186–192. 35 indexed citations
15.
D’Alò, Francesco, Lisa M. Johansen, Erik A. Nelson, et al.. (2003). The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood. 102(9). 3163–3171. 81 indexed citations
16.
Powers, Maureen A., Erica N Evans, Jing Yang, & Sally Kornbluth. (2001). Preparation and Use of Interphase Xenopus Egg Extracts. Current Protocols in Cell Biology. 9(1). Unit 11.10–Unit 11.10. 15 indexed citations
17.
Evans, Erica N. (1997). Reaper-induced apoptosis in a vertebrate system. The EMBO Journal. 16(24). 7372–7381. 71 indexed citations
18.
Evans, Erica N. (1997). Crk is required for apoptosis in Xenopus egg extracts. The EMBO Journal. 16(2). 230–241. 43 indexed citations
19.
Hopwood, Vicky, et al.. (1995). Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. Journal of Infection. 30(2). 153–155. 32 indexed citations
20.
Evans, Erica N, Jessica Cooley, & Eileen Remold‐O’Donnell. (1995). Characterization and Chromosomal Localization of ELANH2, the Gene Encoding Human Monocyte/Neutrophil Elastase Inhibitor. Genomics. 28(2). 235–240. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebastian Herzog Breakdown of academic impact, for papers by Albert G. Tsai Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Pia Ragno Breakdown of academic impact, for papers by Giorgia Simonetti Breakdown of academic impact, for papers by Donatella Venturelli Breakdown of academic impact, for papers by Zongdong Li Breakdown of academic impact, for papers by Lorraine Tracey Breakdown of academic impact, for papers by Sonia Minuzzo Breakdown of academic impact, for papers by Samuli Eldfors
Rankless by CCL
2026